Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 23Carcinoma, Transitional Cell 22Ureteral Neoplasms 7Urologic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Urogenital Neoplasms 2Urethral Neoplasms 2Peripheral Nervous System Diseases 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 71Irinotecan 67Nivolumab 45Capecitabine 43Specimen Handling 40regorafenib 30trifluridine tipiracil drug combination 29Folfox protocol 29Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 20Gemcitabine 20Trifluridine 19Cisplatin 19Blood Specimen Collection 19tislelizumab 17atezolizumab 17Carboplatin 17balstilimab 16Colonoscopy 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × enfortumab vedotin × 1 year × Clear all
NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡